托伐普坦治疗联合人血白蛋白肝硬化顽固性腹水的临床观察

Clinical Observation of Tolvaptan in Combination with Human Albumin in Treating Refractory Ascites Due to Liver Cirrhosis

摘要: 目的：观察托伐普坦联合人血白蛋白在治疗肝硬化顽固性腹水中的作用。方法：选取我院2019年1月至2020年1月收治的80例肝硬化顽固性腹水患者为研究对象，随机分为实验组与对照组两组，每组40例，对照组给予限钠、常规利尿、输人血白蛋白等基础治疗，观察组在对照组基础上加用托伐普坦治疗，对比两组患者治疗前后血钠、尿量、腹围的变化水平。结果：治疗组的血钠、腹围、尿量与对照组的差别具有统计学意义(P < 0.05)，而不良反应差别无明显统计学意义(P > 0.05)。结论：应用托伐普坦联合人血白蛋白治疗肝硬化顽固性腹水，比单纯应用限钠、利尿、输人血白蛋白等治疗措施相比，效果更明显，具有重要临床意义。

Abstract: Objective: To observe the effect of tolvaptan combined with human blood albumin in the treatment of refractory ascites due to cirrhosis. Methods: We Selected 80 cases of liver cirrhosis patients with refractory ascites from our hospital between January 2019 and January 2020 as the research object; then the patients were randomly divided into experimental and control group, and each group had 40 cases. The control group was given sodium limit and conventional foundation treatment such as diuresis, intravenous drip of human albumin protein, but the observation group was not only given treatment as the control group had, but also combined with simvastatin treatment. Consequently, we compared the two groups of patients’ levels of blood sodium, urine and waistline after treatment. Results: The differences of blood sodium, abdominal circumference and urine volume between the treatment group and the control group were statistically significant (P < 0.05), while the differences of adverse reactions had no significance. Conclusion: Compared with sodium restriction, diuresis and human albumin alone, torvartan combined with human albumin in the treatment of refractory ascites due to cirrhosis has more obvious effect and important clinical significance.